These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 34444562)

  • 21. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
    Lachin JM
    Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal timing for an accelerated interim futility analysis incorporating real world data.
    Haine LMF; Murray TA; Koopmeiners JS
    Contemp Clin Trials; 2024 May; 140():107489. PubMed ID: 38461938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive probability methods for interim monitoring in clinical trials with longitudinal outcomes.
    Zhou M; Tang Q; Lang L; Xing J; Tatsuoka K
    Stat Med; 2018 Jun; 37(14):2187-2207. PubMed ID: 29664214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Bayesian adaptive design for clinical trials of rare efficacy outcomes with multiple definitions.
    Golchi S; Willard JJ; Pullenayegum E; Bassani DG; Pell LG; Thorlund K; Roth DE
    Clin Trials; 2022 Dec; 19(6):613-622. PubMed ID: 36408565
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bayesian adaptive design for pediatric clinical trials incorporating a community of prior beliefs.
    Wang Y; Travis J; Gajewski B
    BMC Med Res Methodol; 2022 Apr; 22(1):118. PubMed ID: 35448963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimizing interim analysis timing for Bayesian adaptive commensurate designs.
    Wu X; Xu Y; Carlin BP
    Stat Med; 2020 Feb; 39(4):424-437. PubMed ID: 31799737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of Bayesian and frequentist group-sequential clinical trial designs.
    Stallard N; Todd S; Ryan EG; Gates S
    BMC Med Res Methodol; 2020 Jan; 20(1):4. PubMed ID: 31910813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive probability of success and the assessment of futility in large outcomes trials.
    Trzaskoma B; Sashegyi A
    J Biopharm Stat; 2007; 17(1):45-63. PubMed ID: 17219755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The utility of Bayesian predictive probabilities for interim monitoring of clinical trials.
    Saville BR; Connor JT; Ayers GD; Alvarez J
    Clin Trials; 2014 Aug; 11(4):485-493. PubMed ID: 24872363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Futility stopping in clinical trials, optimality and practical considerations.
    Chang Y; Song T; Monaco J; Ivanova A
    J Biopharm Stat; 2020 Nov; 30(6):1050-1059. PubMed ID: 32926648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Bayesian predictive sample size selection design for single-arm exploratory clinical trials.
    Teramukai S; Daimon T; Zohar S
    Stat Med; 2012 Dec; 31(30):4243-54. PubMed ID: 22807115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of Bayesian vs Frequentist Adaptive Trial Design in the Stroke Hyperglycemia Insulin Network Effort Trial.
    Broglio K; Meurer WJ; Durkalski V; Pauls Q; Connor J; Berry D; Lewis RJ; Johnston KC; Barsan WG
    JAMA Netw Open; 2022 May; 5(5):e2211616. PubMed ID: 35544137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials.
    Wason JM; Trippa L
    Stat Med; 2014 Jun; 33(13):2206-21. PubMed ID: 24421053
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Bayesian Hybrid Adaptive Randomisation Design for Clinical Trials with Survival Outcomes.
    Moatti M; Chevret S; Zohar S; Rosenberger WF
    Methods Inf Med; 2016; 55(1):4-13. PubMed ID: 26404511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Some design considerations incorporating early futility for single-arm clinical trials with time-to-event primary endpoints using Weibull distribution.
    Waleed M; He J; Phadnis MA
    Pharm Stat; 2021 May; 20(3):610-644. PubMed ID: 33565236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Using dichotomized survival data to construct a prior distribution for a Bayesian seamless Phase II/III clinical trial.
    Duputel B; Stallard N; Montestruc F; Zohar S; Ursino M
    Stat Methods Med Res; 2023 May; 32(5):963-977. PubMed ID: 36919403
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bayesian predictive approach to interim monitoring in clinical trials.
    Dmitrienko A; Wang MD
    Stat Med; 2006 Jul; 25(13):2178-95. PubMed ID: 16007570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bayesian two-stage design for phase II oncology trials with binary endpoint.
    Chen L; Pan J; Wu Y; Wang J; Chen F; Zhao J; Chen P
    Stat Med; 2022 May; 41(12):2291-2301. PubMed ID: 35178729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Bayesian piecewise exponential phase II design for monitoring a time-to-event endpoint.
    Qing Y; Thall PF; Yuan Y
    Pharm Stat; 2023 Jan; 22(1):34-44. PubMed ID: 35851545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advantages of Bayesian monitoring methods in deciding whether and when to stop a clinical trial: an example of a neonatal cooling trial.
    Pedroza C; Tyson JE; Das A; Laptook A; Bell EF; Shankaran S;
    Trials; 2016 Jul; 17(1):335. PubMed ID: 27450203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.